176 related articles for article (PubMed ID: 10091528)
1. [HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease].
da Silva PM
Rev Port Cardiol; 1999 Jan; 18(1):65-76. PubMed ID: 10091528
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological effects of HMG-CoA reductase inhibitors].
Tomita N; Morishita R; Ogihara T
Nihon Rinsho; 2002 May; 60(5):955-61. PubMed ID: 12029999
[TBL] [Abstract][Full Text] [Related]
4. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
Wojakowski W; Gmiński J
Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
6. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
8. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.
Hanefeld M
Int J Clin Pract; 2001; 55(6):399-405. PubMed ID: 11501230
[TBL] [Abstract][Full Text] [Related]
9. Potential therapeutic role of statins in neurological disorders.
Bifulco M; Malfitano AM; Marasco G
Expert Rev Neurother; 2008 May; 8(5):827-37. PubMed ID: 18457539
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
12. Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Kerst LL; Mauro VF
Ann Pharmacother; 2004 Jun; 38(6):1060-4. PubMed ID: 15121997
[TBL] [Abstract][Full Text] [Related]
13. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs.
Manzoni M; Rollini M
Appl Microbiol Biotechnol; 2002 Apr; 58(5):555-64. PubMed ID: 11956737
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitors: a look back and a look ahead.
Davignon J; Montigny M; Dufour R
Can J Cardiol; 1992 Oct; 8(8):843-64. PubMed ID: 1423005
[TBL] [Abstract][Full Text] [Related]
15. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
[TBL] [Abstract][Full Text] [Related]
16. [Safety profile of statins].
Prieto JC
Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins and related pharmacological experimental approaches.
Alegret M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
[TBL] [Abstract][Full Text] [Related]
18. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). HMG-CoA reductase inhibitors: a review of published clinical trials and pharmacoeconomic evaluations.
Int J Technol Assess Health Care; 1998; 14(2):396-8. PubMed ID: 9678976
[No Abstract] [Full Text] [Related]
19. Cardiovascular effects of statins, beyond lipid-lowering properties.
Mihos CG; Pineda AM; Santana O
Pharmacol Res; 2014 Oct; 88():12-9. PubMed ID: 24631782
[TBL] [Abstract][Full Text] [Related]
20. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors.
Blauw GJ; Lagaay AM; Smelt AH; Westendorp RG
Stroke; 1997 May; 28(5):946-50. PubMed ID: 9158630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
